Associated Papers
Impact of chromosomal aberrations detected by chromosome banding analysis in symptomatic Waldenström's macroglobulinemia.
Ito K et al.
Annals of Hematology, 2025
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.
Gustine JN et al.
British Journal of Haematology, 2021
Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom's Macroglobulinemia.
Milanesi S et al.
International Journal of Molecular Sciences, 2020
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Jiménez C et al.
British Journal of Haematology, 2020
High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.
Pillonel V et al.
Leukemia, 2018
29556019 (PubMed )
Supplement: 41375_2018_82_MOESM10_ESM.xlsx › .
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Xu L et al.
Blood, 2017
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
Ballester LY et al.
Clinical Lymphoma, Myeloma & Leukemia, 2016
Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
Poulain S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Xu L et al.
British Journal of Haematology, 2016
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
Schmidt J et al.
British Journal of Haematology, 2015
The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y et al.
Leukemia, 2015
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP et al.
Blood, 2014
Select a paper to view details